Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Cystatin M suppresses the malignant phenotype of human MDA-MB-435S cells

Abstract

Proteases are involved in many aspects of tumor progression, including cell survival and proliferation, escape from immune surveillance, cell adhesion and migration, remodeling and invasion of the extracellular matrix. Several lysosomal cysteine proteases have been cloned and shown to be overexpressed in cancer; yet, despite the great potential for development of novel therapeutics, we still know little about the regulation of their proteolytic activity. Cystatins such as cystatin M are potent endogenous protein inhibitors of lysosomal cysteine proteases. Cystatin M is expressed in normal and premalignant human epithelial cells, but not in many cancer cell lines. Here, we examined the effects of cystatin M expression on malignant properties of human breast carcinoma MDA-MB-435S cells. Cystatin M was found to significantly reduce in vitro: cell proliferation, migration, Matrigel invasion, and adhesion to endothelial cells. Reduction of cell proliferation and adhesion to an endothelial cell monolayer were both independent of the inhibition of lysosomal cysteine proteases. In contrast, cell migration and matrix invasion seemed to rely on lysosomal cysteine proteases, as both recombinant cystatin M and E64 were able to block these processes. This study provides the first evidence that cystatin M may play important roles in safeguarding against human breast cancer.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  • Abrahamson M . (1994). Methods Enzymol., 244, 685–700.

  • Abrahamson M, Barrett AJ, Salvesen G and Grubb A . (1986). J. Biol. Chem., 261, 11282–11289.

  • Al-Mehdi AB, Tozawa K, Fisher AB, Shientag L, Lee A and Muschel RJ . (2000). Nat. Med., 6, 100–102.

  • Alvarez-Fernandez M, Barrett AJ, Gerhartz B, Dando PM, Ni J and Abrahamson M . (1999). J. Biol. Chem., 274, 19195–19203.

  • Barrett AJ, Rawlings ND, Davies ME, Machleidt W, Salvesen G and Turk V . (1986). Proteinase Inhibitors, Barrett AJ and Salvesen G (eds). Elsevier Science Publishers: Amsterdam.

    Google Scholar 

  • Bell ET, Featherstone JD and Bell JE . (1989). Arch. Biochem. Biophys., 271, 359–365.

  • Boike G, Lah T, Sloane BF, Rozhin J, Honn K, Guirguis R, Stracke ML, Liotta LA and Schiffmann E . (1992). Melanoma Res., 1, 333–340.

  • Bromme D and Kaleta J . (2002). Curr. Pharm. Des., 8, 1639–1658.

  • Bromme D, Okamoto K, Wang BB and Biroc S . (1996). J. Biol. Chem., 271, 2126–2132.

  • Brunner N, Pyke C, Hansen CH, Romer J, Grondahl-Hansen J and Dano K . (1994). Cancer Treat Res., 71, 299–309.

  • Buck MR, Karustis DG, Day NA, Honn KV and Sloane BF . (1992). Biochem. J., 282, 273–278.

  • Buttle DJ, Murata M, Knight CG and Barrett AJ . (1992). Arch. Biochem. Biophys., 299, 377–380.

  • Chapman HA, Riese RJ and Shi GP . (1997). Annu. Rev. Physiol., 59, 63–88.

  • Chen JM, Dando PM, Rawlings ND, Brown MA, Young NE, Stevens RA, Hewitt E, Watts C and Barrett AJ . (1997). J. Biol. Chem., 272, 8090–8098.

  • Chen JM, Fortunato M, Stevens RA and Barrett AJ . (2001). Biol. Chem., 382, 777–783.

  • Coulibaly S, Schwihla H, Abrahamson M, Albini A, Cerni C, Clark JL, Ng KM, Katunuma N, Schlappack O, Glossl J and Mach L . (1999). Int. J. Cancer, 83, 526–531.

  • DeClerck YA and Imren S . (1994). Eur. J. Cancer, 30A, 2170–2180.

  • Ekiel I, Abrahamson M, Fulton DB, Lindahl P, Storer AC, Levadoux W, Lafrance M, Labelle S, Pomerleau Y, Groleau D, LeSauteur L and Gehring K . (1997). J. Mol. Biol., 271, 266–277.

  • Goretzki L, Schmitt M, Mann K, Calvete J, Chucholowski N, Kramer M, Gunzler WA, Janicke F and Graeff H . (1992). FEBS Lett., 297, 112–118.

  • Guinec N, Dalet-Fumeron V and Pagano M . (1993). Biol. Chem. Hoppe Seyler, 374, 1135–1146.

  • Guo M, Mathieu PA, Linebaugh B, Sloane BF and Reiners Jr JJ . (2002). J. Biol. Chem., 277, 14829–14837.

  • Hendrix MJ, Seftor EA, Seftor RE and Fidler IJ . (1987). Cancer Lett., 38, 137–147.

  • Hulkower KI, Butler CC, Linebaugh BE, Klaus JL, Keppler D, Giranda VL and Sloane BF . (2000). Eur. J. Biochem., 267, 4165–4170.

  • Kembhavi AA, Buttle DJ, Knight CG and Barrett AJ . (1993). Arch. Biochem. Biophys., 303, 208–213.

  • Keppler D, Sameni M, Moin K, Mikkelsen T, Diglio CA and Sloane BF . (1996). Biochem. Cell Biol., 74, 799–810.

  • Keppler D and Sloane BF . (1996). Enzyme Protein, 49, 94–105.

  • Keppler D, Sordat B and Sierra F . (1997). Mech. Ageing Dev., 98, 151–165.

  • Keppler D, Waridel P, Abrahamson M, Bachmann D, Berdoz J and Sordat B . (1994). Biochim. Biophys. Acta, 1226, 117–125.

  • Kevil CG, Patel RP and Bullard DC . (2001). Am. J. Physiol. Cell Physiol., 281, C1442–C1447.

  • Kevil CG, Payne DK, Mire E and Alexander JS . (1998). J. Biol. Chem., 273, 15099–15103.

  • Kobayashi H, Ohi H, Sugimura M, Shinohara H, Fujii T and Terao T . (1992). Cancer Res., 52, 3610–3614.

  • Kolkhorst V, Sturzebecher J and Wiederanders B . (1998). J. Cancer Res. Clin. Oncol., 124, 598–606.

  • Konduri SD, Yanamandra N, Siddique K, Joseph A, Dinh DH, Olivero WC, Gujrati M, Kouraklis G, Swaroop A, Kyritsis AP and Rao JS . (2002). Oncogene, 21, 8705–8712.

  • Laber B, Krieglstein K, Henschen A, Kos J, Turk V, Huber R and Bode W . (1989). FEBS Lett., 248, 162–168.

  • Leung-Tack J, Tavera C, Gensac MC, Martinez J and Colle A . (1990). Exp. Cell Res., 188, 16–22.

  • Lin R, Nagai Y, Sladek R, Bastien Y, Ho J, Petrecca K, Sotiropoulou G, Diamandis EP, Hudson TJ and White JH . (2002). Mol. Endocrinol., 16, 1243–1256.

  • Linebaugh BE, Sameni M, Day NA, Sloane BF and Keppler D . (1999). Eur. J. Biochem., 264, 100–109.

  • Liotta LA and Stetler-Stevenson WG . (1991). Cancer Res., 51, 5054s–5059s.

  • Liu C, Sun C, Huang H, Janda K and Edgington T . (2003). Cancer Res., 63, 2957–2964.

  • Liu Z, Brattain MG and Appert H . (1997). Biochem. Biophys. Res. Commun., 231, 283–289.

  • Maciewicz RA, Wotton SF, Etherington DJ and Duance VC . (1990). FEBS Lett., 269, 189–193.

  • Mai J, Sameni M, Mikkelsen T and Sloane BF . (2002). Biol. Chem., 383, 1407–1413.

  • Mason RW, Stabley DL, Picerno GN, Frenck J, Xing S, Bertenshaw GP and Sol-Church K . (2002). Biol. Chem., 383, 1113–1118.

  • Merz GS, Benedikz E, Schwenk V, Johansen TE, Vogel LK, Rushbrook JI and Wisniewski HM . (1997). J. Cell. Physiol., 173, 423–432.

  • Ni J, Abrahamson M, Zhang M, Fernandez MA, Grubb A, Su J, Yu GL, Li Y, Parmelee D, Xing L, Coleman TA, Gentz S, Thotakura R, Nguyen N, Hesselberg M and Gentz R . (1997). J. Biol. Chem., 272, 10853–10858.

  • Poste G and Fidler IJ . (1980). Nature, 283, 139–146.

  • Price JE and Zhang RD . (1990). Cancer Metastasis Rev., 8, 285–297.

  • Puente XS, Sanchez LM, Overall CM and Lopez-Otin C . (2003). Nat. Rev. Genet., 4, 544–558.

  • Redwood SM, Liu BC, Weiss RE, Hodge DE and Droller MJ . (1992). Cancer, 69, 1212–1219.

  • Roshy S, Sloane BF and Moin K . (2003). Cancer Metastasis Rev., 22, 271–286.

  • Sager R . (1997). Proc. Natl. Acad. Sci. USA, 94, 952–955.

  • Sameni M, Moin K and Sloane BF . (2000). Neoplasia, 2, 496–504.

  • Sexton PS and Cox JL . (1997). Melanoma Res., 7, 97–101.

  • Sotiropoulou G, Anisowicz A and Sager R . (1997). J. Biol. Chem., 272, 903–910.

  • Sun Q . (1989). Exp. Cell. Res., 180, 150–160.

  • Taupin P, Ray J, Fischer WH, Suhr ST, Haakansson K, Grubb A and Gage FH . (2000). Neuron, 28, 385–397.

  • Tavera C, Leung-Tack J, Prevot D, Gensac MC, Martinez J, Fulcrand P and Colle A . (1992). Biochem. Biophys. Res. Commun., 182, 1082–1088.

  • Thompson EW, Paik S, Brunner N, Sommers CL, Zugmaier G, Clarke R, Shima TB, Torri J, Donahue S and Lippman ME . (1992). J. Cell. Physiol., 150, 534–544.

  • Turk V and Bode W . (1991). FEBS Lett., 285, 213–219.

  • Vigneswaran N, Wu J and Zacharias W . (2003). Oral Oncol., 39, 559–568.

  • Villadangos JA, Bryant RA, Deussing J, Driessen C, Lennon-Dumenil AM, Riese RJ, Roth W, Saftig P, Shi GP, Chapman HA, Peters C and Ploegh HL . (1999). Immunol. Rev., 172, 109–120.

  • Zeeuwen PL, Van Vlijmen-Willems IM, Egami H and Schalkwijk J . (2002). Br. J. Dermatol., 147, 87–94.

  • Zeeuwen PL, Van Vlijmen-Willems IM, Jansen BJ, Sotiropoulou G, Curfs JH, Meis JF, Janssen JJ, Van Ruissen F and Schalkwijk J . (2001). J. Invest. Dermatol., 116, 693–701.

Download references

Acknowledgements

We wish to acknowledge the generous gift of human melanoma cell lines from Dr Meenhard Herlyn (The Wistar Institute, Philadelphia, PA, USA) and of cystatin C antibodies from Dr Magnus Abrahamson (University of Lund, Lund, Sweden). Our warmest thanks are also due to Dr Avraham Raz, for his lively input throughout this work. Part of this study was supported by a Virtual Discovery Grant (DK) from the Barbara Ann Karmanos Cancer Institute and Research Grants CA91785 (DK) and CA36481 (BFS) from the National Cancer Institute.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Daniel Keppler.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shridhar, R., Zhang, J., Song, J. et al. Cystatin M suppresses the malignant phenotype of human MDA-MB-435S cells. Oncogene 23, 2206–2215 (2004). https://doi.org/10.1038/sj.onc.1207340

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1207340

Keywords

This article is cited by

Search

Quick links